Table 1. Characteristics of patients with CML who had Omicron infection .
CKD: chronic kidney disease; PMH: past medical history; CML: chronic myeloid leukemia; MPN, myeloproliferative neoplasm; AKI, acute kidney injury; TLS, tumor lysis syndrome.
| Age | Gender | PMH or comorbidities | Duration of disease (MPN) | Active treatment for CML | Vaccination status | Vaccine type received | Previous COVID-19 infection | Previous thrombosis or hemorrhage with COVID -19 | Other complications with previous COVID-19 infection | Omicron COVID-19 severity | Hospitalization | Complications and outcome |
| 32 | Male | None | 1 year | Ponatinib | 2 doses | Pfizer | None | None | None | Mild | Yes | Good outcome |
| 45 | Male | Hypothyroidism | 5 years | Imatinib, hydroxyurea | None | None | None | None | None | Mild | Yes | AKI, TLS |
| 28 | Male | None | 2 years | Dasatinib | 2 doses | Moderna | None | None | None | Mild | None | Good outcome |
| 38 | Female | None | 4 years | Hydroxyurea | None | None | None | None | None | Mild | Yes | Good outcome |
| 42 | Male | None | 5 years | Imatinib | 2 doses | Moderna | None | None | None | Mild | None | Good outcome |
| 42 | Male | None | 7 years | Imatinib | 3 doses | Pfizer | None | None | None | Mild | None | Good outcome |
| 45 | Male | Hypertension, asthma | 2 years | Imatinib | 2 doses | Pfizer | None | None | None | Mild | None | Good outcome |
| 52 | Male | Hypertension, diabetes, dyslipidemia | 6 years | Dasatinib | None | None | None | None | None | Mild | None | Good outcome |
| 65 | Male | Osteomyelitis, diabetes, dyslipidemia, CKD, peripheral vascular disease | 10 years | Nilotinib | None | None | None | None | None | Mild | None | Good outcome |
| 45 | Male | None | 3 years | Nilotinib | 3 doses | Pfizer | None | None | None | Mild | None | Good outcome |
| 61 | Male | Hypercholestrelemia | 5 years | Imatinib | 3 doses | Pfizer | None | None | None | Mild | None | Good outcome |